Sydney, Australia – Celosia Therapeutics announced today the first patient has been dosed in its Phase 1b KOANEWA clinical trial, marking a significant step forward in the development of CTx1000, an investigational genetic medicine designed to treat amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND). The trial, currently underway at the Neurology Department of Macquarie University Hospital in Sydney, offers a new avenue of hope for individuals battling this progressive and currently incurable neurodegenerative disease. This represents a crucial milestone in the pursuit of disease-modifying therapies for ALS, a condition affecting an estimated 30,000 Americans, according to the ALS Association.
ALS progressively destroys motor neurons, the nerve cells that control voluntary muscle movement, leading to paralysis and eventually death. Currently, treatment options primarily focus on managing symptoms and slowing disease progression, but a truly effective therapy remains elusive. The urgency for new treatments is underscored by the relatively rapid disease course, with a median survival time of just two to five years after diagnosis. The KOANEWA trial focuses on a novel approach, targeting a key driver of the disease at the genetic level.
Targeting TDP-43: A New Approach to ALS Treatment
CTx1000 is designed to address the pathological accumulation of the TDP-43 protein, a hallmark of most ALS cases. Approximately 90-95% of ALS patients exhibit TDP-43 misfolding and aggregation within motor neurons, disrupting their function and contributing to cell death. The therapeutic strategy behind CTx1000, developed from groundbreaking research by Professors Lars Ittner and Yazi Ke, aims to selectively bind and clear these toxic forms of TDP-43. Their initial discovery, reported in the journal Neuron in February 2024, identified a unique binder to the protein, paving the way for the development of this genetic medicine. Neuron
“This study is a major milestone for our research program, advancing a novel disease-modifying therapeutic strategy into the clinic that, for the first time, directly targets a fundamental disease mechanism in ALS—the pathological accumulation of TDP-43,” said Prof. Lars Ittner, Chief Medical Officer at Celosia and Director of the Macquarie University Dementia Research Centre. “Evaluating CTx1000 in people living with ALS will enable us to assess the safety of this approach while also exploring its potential to therapeutically address one of the key drivers of disease.”
Understanding the KOANEWA Trial
The KOANEWA trial is a first-in-human, open-label Phase 1b study, meaning all participants will receive CTx1000. The primary goal of this phase is to evaluate the safety and tolerability of a single administration of the genetic medicine in individuals diagnosed with ALS. Researchers will closely monitor participants for any adverse effects and assess how well the body tolerates the treatment. ClinicalTrials.gov provides detailed information about the trial protocol and enrollment criteria.
Beyond safety, the study will also collect data on biomarkers and clinical measures to provide preliminary insights into CTx1000’s potential efficacy. These exploratory endpoints will help researchers understand how the treatment impacts the underlying disease process and whether it shows signs of slowing or reversing disease progression. The open-label design means both researchers and participants are aware of the treatment being administered, which can influence outcomes, but is common in early-phase safety trials.
Preclinical Successes Fuel Clinical Hope
The decision to move CTx1000 into human trials is supported by promising results from preclinical studies. In multiple ALS models, the genetic medicine demonstrated the ability to halt disease progression, even at advanced stages. In some instances, CTx1000 even partially reversed disease manifestations, offering a glimpse of its potential therapeutic impact. These findings, while encouraging, must be validated through rigorous clinical trials in humans.
Celosia Therapeutics and the Future of ALS Research
Celosia Therapeutics, an Australian biotech company specializing in gene therapies for neurodegenerative diseases, is leading the development of CTx1000. The company’s commitment to innovative research and development is driven by the urgent require for effective ALS treatments. Dr. Kathryn Sunn, Chief Executive Officer at Celosia Therapeutics, emphasized the significance of this milestone. “ALS is a progressive and ultimately fatal neurodegenerative disease with limited therapeutic options,” she stated. “The initiation of dosing in the KOANEWA study marks an vital milestone for Celosia and, most importantly, for the ALS community. Treating the first patient begins the clinical evaluation of this genetic medicine and represents a meaningful step toward a potential disease-modifying therapy for people living with ALS.”
The development of CTx1000 represents a significant investment in ALS research and a beacon of hope for patients and their families. While the road to a cure remains long, this Phase 1b trial marks a critical step forward in understanding and potentially treating this devastating disease. The company plans to continue monitoring the initial participants and will likely expand the trial to include more patients in the coming months, pending safety data review.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. We see essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The next key milestone for Celosia Therapeutics will be the completion of the Phase 1b safety evaluation and the subsequent analysis of preliminary biomarker data. The company anticipates sharing initial findings from the KOANEWA trial in late 2026 or early 2027. We encourage readers to share this information and join the conversation about advancements in ALS research.
